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Introduction
Neurofibromatosis type 1 (NF1) is a neurogenetic condition 
present in approximately 1 in 3000 births.1 Plexiform neu-
rofibromas (pNFs) are present in about half of NF1 cases.2 
These are benign tumours that grow along deep nerves3 and 
are thought to be present from birth.4 They are frequently 
associated with functional and neurological deficits, disfig-
urement and substantial pain.5 There is a lifetime risk of 
malignant transformation in pNFs and they may cause com-
pression of the airways or vital organs. As a source of major 
morbidity in NF1, pNFs have a profound impact on an indi-
vidual’s quality of life (QoL).6
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Abstract
Objective: To explore the impact of plexiform neurofibromas on the lives of adults with neurofibromatosis type 1.
Background: Neurofibromatosis type 1 is a complex neurogenetic syndrome that affects many aspects of health and functioning. 
A common manifestation of neurofibromatosis type 1 is plexiform neurofibromas, non-cancerous tumours that can cause 
disfigurement, pain and neurologic disability. Patient-reported outcome measures used in this condition have addressed symptoms 
and functional ability but not how the condition affects patients’ lives, particularly, their ability to meet their human needs.
Methods: Unstructured qualitative interviews were conducted with adults with neurofibromatosis type 1–associated 
plexiform neurofibromas in the United Kingdom and United States. Interviewees were encouraged to describe how plexiform 
neurofibromas affected their ability to meet their needs. Interviews were audio-recorded and transcribed verbatim. The UK 
and US transcripts were combined and theoretical thematic analysis was conducted.
Results: In all, 42 interviews (United Kingdom = 20, United States = 22) were conducted. Transcripts revealed 696 statements 
on the impact of plexiform neurofibromas on need fulfilment. Five major themes emerged: appearance, relationships, 
independence, role fulfilment and pleasure.
Conclusion: Neurofibromatosis type 1–associated plexiform neurofibromas have a major effect on individuals’ ability to 
meet their needs. An understanding of need fulfilment will complement information generated from traditional patient-
reported outcome measures, particularly in a multi-faceted syndrome such as neurofibromatosis type 1.
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Currently, there is no cure for pNFs. Surgical resection is 
the best therapeutic option for symptomatic pNFs. However, 
surgery can be challenging and is not always technically pos-
sible.7 Surgery is unlikely to result in permanent removal of 
the tumour and may cause further complications including 
nerve damage and functional impairment.8–10 There are mul-
tiple recent clinical trials designed to stop the growth, reduce 
the size and improve the symptoms of pNFs (e.g. 
NCT02177825, NCT03231306, NCT02407405, 
NCT03326388, NCT0239075 and NCT01362803). These 
trials used some form of tumour size measurement as the 
endpoint for the therapeutic study, as radiographic response 
is an important marker of drug activity. However, it is also 
important to demonstrate that treatment results in partici-
pants feeling better to add context and meaningful clinical 
impact to imaging improvement in clinical studies.
In addition to imaging tumour response, common out-
comes employed in clinical trials include assessment of 
signs, symptoms and functions.11 Such data are commonly 
collected via patient-reported outcome measures (PROMs). 
Most PROMs assess Health-related Quality of Life (HRQL). 
This construct consists of a variety of different impairments 
and functional limitations resulting from disease.12
Several studies have looked at the impact of NF1 on 
HRQL.13–35 Most of these studies focused on children and 
adolescents.
QoL is a distinct outcome from HRQL. Rather than pro-
ducing a profile of symptoms and functional limitations, QoL 
provides a holistic assessment of the value of an individual’s 
life in the context of their health status. The needs-based 
model36 is a widely operationalised approach to QoL meas-
urement in health research. The model was derived from 
research conducted with depressed and recently recovered 
depressed participants.37 Qualitative interviews revealed that 
individuals’ experiences of depression were described in 
terms of the needs that they were unable to meet. The needs-
based model postulates that life gains its quality from our 
ability to fulfil basic human needs. An individual is consid-
ered to have poor QoL when few needs are satisfied.36 The 
impairments and functional limitations imposed by disease 
prevent needs from being fulfilled. Consequently, a needs-
based approach allows the impacts of disease to be directly 
assessed rather than inferred. The needs-based model forms 
the theoretical basis for this study. In addition to providing 
insight into the impact of NF1-associated pNFs on the lives of 
patients, the study was also used to develop the content for a 
patient-reported outcome (PRO) measure suitable for use 
with this patient group. Such a measure would be used in con-
junction with other outcome measures in therapeutic trials.
Methods
Ethics approval
In the United Kingdom, ethics committee approval was 
obtained from North West-Liverpool Central Research Ethics 
Committee (14/NW/0279). In the United States, approval was 
granted by the Johns Hopkins University School of Medicine 
(JHU-SOM) Institutional Review Board.
Participants
Individuals with NF1 (defined by meeting clinical criteria or 
positive genetic testing), >18 years, with at least one pNF in 
any location, were eligible for the study. A pNF was defined as 
a neurofibroma that has grown along the length of a nerve and 
may involve multiple fascicles and branches; or a spinal neu-
rofibroma that involves two or more levels with connection 
between the levels or extending laterally along the nerve; or a 
skin thickness neurofibroma that measures >3 cm on longest 
diameter by visual examination, palpation or two-dimensional 
(2D) magnetic resonance (MR) imaging; or >3 mL by volu-
metric MR imaging. Potential participants were identified 
through convenience sampling from the clinics they attended: 
Saint Mary’s Hospital, Manchester and Johns Hopkins 
Comprehensive Neurofibromatosis Centre, Baltimore. Patients 
were sent a letter in the post inviting them to participate in the 
study. Those interested were asked to contact the local research-
ers to arrange a convenient date and time for the interview. In 
the United Kingdom, interviewees were given the option of 
being interviewed in their own home, the offices of Galen 
Research or in a private room at Saint Mary’s Hospital. US 
interviews were conducted at Johns Hopkins Comprehensive 
Neurofibromatosis Centre. Individuals with cognitive difficul-
ties who were unable to give consent were not enrolled. All 
participants provided written informed consent.
Patient interviews
One-to-one unstructured, qualitative interviews were con-
ducted by three male and one female interviewers (aged 
24–63 years), including S.P.M. and J.W. All interviewers 
have a degree in psychology and extensive experience in 
conducting qualitative interviews with patients. At the begin-
ning of each interview, the interviewer introduced his/herself 
and explained their role and the purpose of the interview, 
which was to explore the ways in which pNFs and their treat-
ment impacted the lives of patients. In instances where par-
ticipants spoke of the symptoms or functional limitations 
caused by their pNFs, they were encouraged to explain how 
these affected their ability to meet their needs.
Previous qualitative research has demonstrated that satura-
tion of information can be achieved with 30 participants.38,39 
The aim was to recruit a combined total of 40 participants 
from the United Kingdom and United States, in case there 
were any major differences in outcome between countries.
Data analysis
The UK and US data were combined for analysis. Interviews 
were audio-recorded and transcribed verbatim with identi-
fying information omitted from the transcripts to ensure 
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participants’ anonymity. Theoretical thematic analysis,40 
guided by the needs-based model of QoL, was performed on 
the transcripts. Four members of the research team were 
involved in analysing and coding the data. Qualitative anal-
ysis software was not employed. Each transcript was ana-
lysed independently by two of these four researchers (who 
had not interviewed the respondent), to reduce the risk of 
missing important aspects of the interviews. Issues raised by 
patients were grouped into themes, derived from the current 
transcripts. The research team in the United Kingdom and a 
US NF clinician then worked together to refine the themes. 
For reporting purposes, relevant statements were grouped 
into themes that arose from the analyses of the interview 
transcripts.
Results
Participants
Demographic and disease information for the sample are 
presented in Table 1. The sample consisted of 42 participants 
with NF1-associated pNFs from the United Kingdom and 
United States. None of the interviews had to be terminated at 
the request of the interviewee. The duration of the interviews 
ranged from 10 to 90 min.
Interview findings
The interview transcripts revealed 696 statements related to the 
impact of pNFs on need fulfilment. These statements were 
grouped into specific issues and then merged into broad themes. 
For example, issues such as parenting, employment and 
responsibility were combined into the theme of ‘role fulfil-
ment’. The five major themes derived from the analyses were 
appearance, relationships, independence, role fulfilment and 
pleasure. These themes covered all issues identified from the 
interviews. It should be noted that the themes do not describe 
needs themselves but are enablers of need fulfilment.
Comparison between outcomes of UK and US interviews. An 
analysis was undertaken to compare the outcome of inter-
views in the two countries. Only four examples were found 
where a specific issue was raised in one country only. UK 
interviewees commented on missing out on opportunities in 
life. In the United States, some participants expressed con-
cerns about being asked by others about their condition, 
being unable to fill their time and being touched (physically) 
by other people. In all other respects, the interviewees in 
each country raised the same issues when describing the 
impact of their condition. The following sections report the 
main outcomes of the qualitative interviews.
Appearance. The way we look affects needs such as self-
confidence and self-esteem, identity, approachability, rela-
tionship building and employability. Interviewees revealed 
that their pNFs attracted much attention from strangers, who 
stared at the disfigurement or made hurtful remarks about 
their appearance:
I get so many nasty comments … It can be in a supermarket, it 
can be walking to the town, it can be in a restaurant. You name 
it – somebody will make at least one comment. (United Kingdom, 
female, aged 45 years)
Feelings of insecurity and self-consciousness resulted 
from these reactions. Respondents expressed discomfort 
with the way they looked and felt unattractive because of 
their pNF. Some reported avoiding seeing themselves in a 
mirror:
I’m not okay with my body … I don’t love myself. (United States, 
female, aged 22 years)
Participants expressed that whenever possible, they tried 
to ensure that their pNFs were not visible to others by cover-
ing them with clothing. Where clothes could not achieve 
this, the fear of others’ reactions prevented participants from 
taking part in certain activities, such as swimming:
Table 1. Interviewee demographic and disease information.
UK (n = 20) US (n = 22)
Age (years)
 Mean (SD) 42.3 (13.4) 40.2 (11.4)
 Range 20.7–69.2 22.4–63.9
Sex (%)
 Male 9 (45.0) 12 (54.5)
 Female 11 (55.0) 10 (45.4)
Marital status (%)
 Married/living as 10 (50.0) 14 (63.6)
 Single 9 (45.0) 7 (31.8)
 Missing 1 (5.0) 1 (4.6)
Work status (%)
 Full-time employment 11 (55.0) 13 (59.1)
 Part-time 1 (5.0) 3 (13.6)
 Retired 3 (15.0) 1 (4.5)
 Homemaker 0 1 (4.5)
 Long-term sick leave 5 (25.0) 1 (4.5)
 Other 0 3 (13.6)
Perceived general health (%)
 Very good 7 (35.0) 6 (27.3)
 Good 4 (20.0) 11 (50.0)
 Fair 5 (25.0) 2 (9.1)
 Poor 4 (20.0) 3 (13.6)
Perceived disease severity (%)
 Mild 4 (20.0) 10 (45.5)
 Moderate 2 (10.0) 7 (31.8)
 Severe 10 (50.0) 2 (9.1)
 Very severe 4 (20.0) 3 (13.6)
Receiving treatment (%)
 Yes 13 (65.0) 9 (40.9)
 No 7 (35.0) 13 (59.1)
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If I went on holiday I wouldn’t wear like a bikini or anything … 
because I’d be like self-conscious to show it. (United Kingdom, 
female, aged 20 years)
I wouldn’t go swimming because of the way my body looks and 
because of them laughing. (United Kingdom, male, aged 28 years).
Some interviewees reported being reluctant to leave the 
house for fear of people reacting to their appearance. Since 
social situations were considered stressful, participants often 
opted to stay indoors:
So now it’s like I cannot be bothered going out because I can’t 
handle the abuse all the time. (United Kingdom, female, aged 
45 years)
If you walk into a place, you kind of worry what they’re thinking. 
(United Kingdom, male, aged 41 years)
On occasions where participants did socialise, they 
reported feeling uncomfortable and unable to enjoy 
themselves:
I was anxious about going to different places and meeting 
new people, even at work, moving to new departments, going 
on holiday, going for nights out, and it’s just always just a 
worry and then I’m just on tenterhooks all night and during 
these social occasions. (United Kingdom, female, aged 
40 years)
Relationships. Forming relationships is a fundamental ena-
bler of need fulfilment. They can satisfy several needs such 
as physical contact, fun, love, intimacy, appreciation, respect 
and support in coping with problems.
Interviewees explained how their attitude towards their 
pNFs affected their relationships with partners, family and 
friends. It was common for participants to reveal that they 
took their frustration out on people to whom they were emo-
tionally close:
They really don’t do anything it’s just they’re there and I have to 
take my anger out on somebody and that’s what I do. I usually get 
mad at them for no reason. (United States, female, aged 35 years)
Not being physically able to join in activities with fam-
ily and friends was another factor affecting relationships. 
Interviewees recognised the effect that this had on 
others:
I think it upsets my husband that I will not go out. (United 
Kingdom, female aged 45 years)
Participants revealed how their pNFs resulted in con-
stantly staying home and having to decline invitations to 
social outings with family and friends. This placed great 
restrictions on their social life and ability to take part in 
activities they enjoyed:
I want to be able to get out, do this and do that. I’m just stuck in 
the house all alone. (United States, female, aged 35 years)
People with NF1 reported feeling that they were letting 
people down on occasions when they were unable to spend 
time with their loved ones:
I’m missing out on my friends because … I’m in so much pain. 
(United States, female, aged 35 years)
This frequently resulted in feelings of guilt. The impact of 
their condition on participants’ intimate relations was also 
discussed in the interviews:
My partner’s not allowed to see me with no underwear or no 
clothes on … if we do anything it’s in the dark. (United Kingdom, 
female, aged 23 years)
For those without partners, interviewees reported that 
their condition interfered with dating, to the extent that 
they were hesitant or no longer willing to seek 
relationships:
I’ve just even held back from dating and relationships because 
of it. (United States, male, aged 42 years)
Interviewees attributed the breakdown of past romantic 
relationships to the pNFs:
I was going out with someone quite steady for a while but in the 
end I just ended it just because of the way I was and the way I 
felt about myself. (United Kingdom, male, aged 41 years)
Interviewees revealed that they found meeting new peo-
ple difficult because of a lack of confidence:
So like meeting people, new relationships, I’ve no confidence 
whatsoever. (United Kingdom, female, aged 47 years)
For some participants, their pNFs had such an impact that 
they reported being generally reluctant to establish any form 
of relationship with others.
Independence. This quality is fundamental to autonomy and 
is related to self-control, resolve, freedom and achievement. 
Due to the unpredictable nature of their pNFs, interviewees 
reported restrictions on their independence. The associated 
pain and reduced mobility limited patient’s ability to make 
plans and contributed to feelings of a lack of control over 
their situation:
I couldn’t plan to go on a night out from now until say Saturday, 
because if I plan for a night out on a Saturday I could be ill with 
pain. (United Kingdom, female, aged 23 years)
Participants felt dependent on other people. Accepting 
that they needed assistance from others was difficult:
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You’ve got to depend on people to do stuff for you. I’m not that 
type of person, I like to do everything on my own, you know, for 
my personal needs. I like to take care of that myself. But it’s hard 
to do. You’ve got to get somebody to do it for you. You’ve got to 
tell somebody what your problem is, and they’ve got to help you. 
You really don’t want that, you want to keep that to yourself. 
(United States, female, aged 35 years)
People with NF1-associated pNFs who experienced pain 
and discomfort found it difficult to devote attention to other 
issues. Feelings of preoccupation with their pNFs were com-
monly expressed in interviews:
I think it’s just in the back of my mind all the time. (United 
Kingdom, female, aged 23 years)
Role fulfilment. Having roles and being able to meet others’ 
expectations are fundamental needs for our lives. Our roles 
guide how we behave and give us influence and status. Those 
participants unable to work explained that they missed being 
of value and giving something back to the world:
I do miss being able to be, like, a productive member of society. 
(United States, female, aged 36 years)
It was clear from the interviews that employment pro-
vides a means of fulfilling needs:
I miss my friends. I miss my colleagues. I miss the stress of 
hurrying up and trying to get things done, you know being busy. 
I find myself really bored, lately. So I do miss work. (United 
States, female, aged 35 years)
Interviewees stated that their pNFs prevented them from 
living life to the full:
I think I’ve missed out on certain opportunities because there’s 
certain things I’ve not been able to do because of my condition. 
(United Kingdom, male, aged 51 years)
Some participants had decided not to have children. After 
experiencing living with the condition, they felt it would be 
unfair to take the risk of inflicting pNFs on a child. Their 
decision prevented the role of a parent being fulfilled:
I wouldn’t take the risk of passing it on because it’s not pleasant 
and I want to do everything in my power to prevent it being 
passed on through me. (United Kingdom, female, aged 35 years)
I will never have kids. Never. I wouldn’t like my kids to grow up 
like I have, what I’ve got; no chance. (United Kingdom, male, 
aged 41 years)
Others who did have children reported feeling that they 
were unable to fulfil their parental role:
I’m unable to walk far. I can’t play with my kids or do nothing 
like that. (United States, female, aged 36 years)
I can’t go get my daughter from the bus stop or school. (United 
States, female, aged 35 years)
For one parent, passing NF1 onto his daughter was some-
thing that he could not forgive himself for:
I hate myself for it, like, giving her that, because it’s not very 
nice having it. (United Kingdom, male, aged 51 years)
Interviewees revealed that their pNFs restricted them 
from fulfilling a variety of roles at home:
being a mom, I’m supposed to be there, I’m supposed to cook, 
I’m supposed to do all this, but I’m unable to do it. (United 
States, female, aged 35 years)
Pleasure. The pNFs had a considerable impact on the ability 
to meet needs for pleasure and relaxation. Participants 
expressed no longer being able to take part in hobbies that 
they once loved due to various problems:
I used to do ballet, tap, jazz … and as the lump got bigger, 
through my younger age and teens, it became more apparent so 
I couldn’t wear the correct clothing for what the dance teachers 
used to say you had to wear. (United Kingdom, female, aged 
34 years)
Swimming was a favourite activity that interviewees gen-
erally avoided as they were unable to cover their pNFs:
it’s just the nature of going swimming and the people in there … 
I wish I could go. (United Kingdom, female, aged 34 years)
Increasing pain and mobility problems also caused hob-
bies to be abandoned:
I’d love to be able to go back into dancing but I can’t do it, it’s 
too – it’s causing me too much pain. (United Kingdom, female, 
aged 23 years)
Socialising became less pleasurable due to discomfort 
and self-consciousness. Individuals often preferred to avoid 
these situations leading to a restricted social life. Figure 1 
shows the percentage of interviewees who made at least one 
comment within each of the five themes identified.
Discussion
Qualitative research can provide rich insight into the patient-
perceived impact of illness and provide meaningful infor-
mation about the effects of treatment on patients’ perceived 
QoL.38,39,41 People living with a condition are the best, and 
arguably the only, valid judges of how it impacts their QoL. 
The data gathered in this study identified the pertinent and 
specific concerns of interviewees with NF1-associated 
pNFs. Specifically, it identified how the condition influ-
ences need fulfilment.
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The qualitative interviews conducted focused on how the 
symptoms and functional limitations resulting from pNFs 
impacted the ability of people to meet their needs. 
Consequently, the interviewees decided which of these 
impacts were most important for them. This is a unique per-
spective that adds depth and context to the information col-
lected by existing HRQL measures. For example, one study 
asked clinical experts which issues were likely to be of 
importance to patients.33 Interviewees were then asked to 
indicate which of these issues they considered most impor-
tant. Adults included in the study (n = 16) selected pain, anxi-
ety, disfigurement, stigma, body image and physical 
functioning most frequently from the options provided. This 
greater focus on the symptoms of the disease reflects the 
method by which the topics were selected.
In this study, interviews were conducted in the United 
Kingdom and the United States, allowing cross-cultural dif-
ferences in the patient-perceived impact of pNFs to be 
explored. Data analysis revealed that the same needs were 
impeded in both sets of participants. This supports the tenet 
of the needs-based model which argues that human needs are 
universal.
All people with NF1 should be monitored by a specialist 
at least annually. However, adults with mild disease are far 
less likely to have complications and may elect not to attend 
a specialist NF1 clinic.42 It is also possible that some chil-
dren in the population, with mild disease, may not have been 
diagnosed. Consequently, our sample may have missed peo-
ple with less severe disease, who would be unlikely to par-
ticipate in clinical trials. The US sample was recruited from 
a major centre in Baltimore (Johns Hopkins Comprehensive 
Neurofibromatosis Centre). The research team in the United 
Kingdom recruited patients from a major centre treating this 
condition in England and included people from Manchester 
and the surrounding areas. However, every effort was made 
to include adults with a range of ages and perceived disease 
severities and a mix of males and females.
The disfigurement caused by the pNFs was variable in the 
current sample of patients. Some interviewees had few visi-
ble signs of the condition, while others had significant facial 
or other disfigurement. Great emphasis in the study was 
placed on the impact of pNFs rather than that of the common 
benign cutaneous neurofibromas. While these can also be 
disfiguring, clear distinctions were made throughout the 
interviews. Interviewers did report that there was considera-
ble variability in the disfigurement experienced by inter-
viewees. Some patients were able to cover up their pNFs, 
while others were unable to hide them because of their size 
or location (e.g. on the face or neck).
Appearance, relationships, independence, role fulfilment 
and pleasure were identified as particularly important issues 
for people with pNFs. These aspects of life are important to 
people because they are enablers of need fulfilment. For 
example, relationships allow people to identify as part of a 
group, to have status, to communicate, to work as part of a 
team and to form friendships and fall in love. It is interesting 
to relate these issues to those identified in similar qualitative 
work conducted with other patient groups. Appearance and 
relationships are commonly identified as important issues in 
chronic disease. However, additional factors are also identi-
fied, which are related to the specific condition. In depres-
sion, self-value and self-care were important additional areas 
of concern.36 Crohn’s disease patients highlighted the impor-
tance of hygiene and nutrition.43 Role fulfilment, self-image 
and emotional control were identified in interviews with 
patients with ankylosing spondylitis.44 Interviews with psori-
atic patients indicated that emotional stability and freedom 
were areas of concern.45
Figure 1. Percentage of respondents raising each of the interview themes.
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This study differs from previous work in two main 
respects. First, it was not concerned with measuring impair-
ments and functioning directly, but on determining their 
impact on the value of the lives of adult patients.46 Application 
of the needs-based model of QoL worked well as a means of 
categorising the experiences of the interviewees. Second, an 
adult sample was employed. There remains scope for devel-
oping a needs-based measure for children with pNFs, to 
complement the HRQL measures.
Instruments developed from qualitative needs-based 
interviews have been widely used in international clinical tri-
als to determine the value individuals gain from new inter-
ventions.47–49 Such information is necessary to complement 
assessments of safety and efficacy. Furthermore, as needs-
based measures do not focus on symptoms or functions, they 
are also able to show the benefits to patients of non-clinical 
interventions.50–52
The findings from this study provided a pool of items that 
were used to develop the PlexiQoL, an 18-item needs-based 
PRO measure, specific to adults with NF1-associated pNFs. It 
is intended that the PlexiQoL will be used in studies designed 
to evaluate the benefits of interventions (both clinical and non-
clinical) for this patient group. Without disease-specific, relia-
ble and valid outcome measures, it is difficult to establish that 
such interventions are of value to patients. For example, surgi-
cal removal of pNFs is associated with a high risk of damage to 
surrounding vital structures and the risk of significant haemor-
rhage and can lead to extensive, disfiguring scarring.53
Conclusion
This study provides insight into the impact of NF1-associated 
pNFs on the lives of patients. Analysis of qualitative inter-
views revealed that pNFs have a major effect on individuals’ 
ability to meet their basic human needs. The needs identified 
are the aspects of life most likely to be impaired in these 
patients. An understanding of need fulfilment will comple-
ment information generated from traditional health-related 
QoL measures, particularly in a multi-faceted syndrome 
such as NF1.
Acknowledgements
The authors would like to acknowledge the contributions of all the 
interviewees and James Twiss PhD and Matthew Rouse MSc who 
acted as interviewers.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect 
to the research, authorship, and/or publication of this article.
Ethical approval
Ethical approval for this study was obtained from West-Liverpool 
Central Research Ethics Committee (14/NW/0279) in the United 
Kingdom and the Johns Hopkins University School of Medicine 
(JHU-SOM) Institutional Review Board in the United States.
Funding 
The author(s) disclosed receipt of the following financial support 
for the research, authorship, and/or publication of this article: This 
work was supported by the Neurofibromatosis Therapeutic 
Acceleration Programme.
Informed consent
Written informed consent was obtained from all participants before 
being interviewed.
ORCID iD 
Alice Heaney  https://orcid.org/0000-0002-4534-6705
References
 1. Friedman JM. Epidemiology of neurofibromatosis type 1. Am 
J Med Genet 1999; 89(1): 1–6.
 2. Tonsgard JH. Clinical manifestations and management 
of neurofibromatosis type 1. Semin Pediatr Neurol 2006; 
13(1): 2–7.
 3. Korf BR. Plexiform neurofibromas. Am J Med Genet A 1999; 
89: 31–37.
 4. Ferner RE, Huson S and Evans DGR. Neurofibromatoses in 
clinical practice. London: Springer, 2011.
 5. Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: a 
twenty first century perspective. Lancet Neurol 2007; 6(4): 
340–351.
 6. Hirbe AC and Gutmann DH. Neurofibromatosis type 1: a mul-
tidisciplinary approach to care. Lancet Neurol 2014; 13(8): 
834–843.
 7. Babovic-Vuksanovic D, Widemann BC, Dombi E, et al. 
Phase I trial of pirfenidone in children with neurofibroma-
tosis 1 and plexiform neurofibromas. Pediatr Neurol 2007; 
36(5): 293–300.
 8. Canavese F and Krajbich JI. Resection of plexiform neurofi-
bromas in children with neurofibromatosis type 1. J Pediatr 
Orthop 2011; 31(3): 303–311.
 9. Wise JB, Cryer JE, Belasco JB, et al. Management of head 
and neck plexiform neurofibromas in pediatric patients with 
neurofibromatosis type 1. Arch Otolaryngol Head Neck Surg 
2005; 131(8): 712–718.
 10. Prada CE, Rangwala FA, Martin LJ, et al. Pediatric plexiform 
neurofibromas: impact on morbidity and mortality in neurofi-
bromatosis type 1. J Pediatr 2012; 160(3): 461–467.
 11. Blakeley JO, Coons SJ, Corboy JR, et al. Clinical outcome 
assessment in malignant glioma trials: measuring signs, symp-
toms, and functional limitations. Neuro Oncol 2016; 18(Suppl. 
2): ii13–ii20.
 12. Patrick DL and Erikson P. Health status and health policy. 
Oxford, UK: Oxford University Press, 1993.
 13. Graf A, Landolt MA, Mori AC, et al. Quality of life and 
psychological adjustment in children and adolescents 
with neurofibromatosis type 1. J Pediatr 2006; 149(3): 
348–353.
 14. Page PZ, Page GP, Ecosse E, et al. Impact of neurofibromato-
sis 1 on quality of life: a cross-sectional study of 176 American 
cases. Am J Med Genet A 2006; 140(18): 1893–1898.
 15. Oostenbrink R, Spong K, de Goede-Bolder A, et al. Parental 
reports of health-related quality of life in young children 
8 SAGE Open Medicine
with neurofibromatosis type 1: influence of condition spe-
cific determinants. J Pediatr 2007; 151(2): 182–186.
 16. Kodra Y, Giustini S, Divona L, et al. Health-related quality of 
life in patients with neurofibromatosis type 1 – a survey of 129 
Italian patients. Dermatology 2009; 218: 215–220.
 17. Krab LC, Oostenbrink R, De Goede-Bolder A, et al. Health-
related quality of life in children with neurofibromatosis type 
1: contribution of demographic factors, disease-related fac-
tors, and behavior. J Pediatr 2009; 154(3): 420–425.
 18. Wolkenstein P, Rodriguez D, Ferkal S, et al. Impact of neu-
rofibromatosis 1 upon quality of life in childhood: a cross-
sectional study of 79 cases. Br J Dermatol 2009; 160(4): 
844–848.
 19. Stevenson DA and Carey JC. Health-related quality of life 
measures in genetic disorders: an outcome variable for consid-
eration in clinical trials. Am J Med Genet C Semin Med Genet 
2009; 151C(3): 255–260.
 20. Vardarinos A, Zafeiriou DI, Vargiami E, et al. Parental 
reports of health-related quality of life in Greek children with 
neurofibromatosis type 1. J Pediatr 2009; 155(3): 453; author 
reply 454.
 21. Gilboa Y, Rosenblum S, Fattal-Valevski A, et al. Application 
of the International Classification of Functioning, Disability 
and Health in children with neurofibromatosis type 1: a 
review. Dev Med Child Neurol 2010; 52(7): 612–619.
 22. Langenbruch AK, Augustin M, Granström S, et al. Clinical 
and healthcare status of participants with neurofibromatosis 
type 1. Br J Dermatol 2011; 165: 225–227.
 23. Garwood MM, Bernacki JM, Fine KM, et al. Physical, cog-
nitive, and psychosocial predictors of functional disability 
and health-related quality of life in adolescents with neurofi-
bromatosis-1. Pain Res Treat 2012.
 24. Granström S, Langenbruch A, Augustin M, et al. Psychological bur-
den in adult neurofibromatosis type 1 participants: impact of disease 
visibility on body image. Dermatology 2012; 224: 160–167.
 25. Cosyns M, Mortier G, Janssens S, et al. Voice-related quality 
of life in adults with neurofibromatosis type 1. J Voice 2012; 
26(2): e57–e62.
 26. Oates EC, Payne JM, Foster SL, et al. Young Australian adults 
with NF1 have poor access to health care, high complication 
rates, and limited disease knowledge. Am J Med Genet A 2013; 
161A(4): 659–666.
 27. Avery RA and Hardy KK. Vision specific quality of life in 
children with optic pathway gliomas. J Neurooncol 2014; 
116(2): 341–347.
 28. Vranceanu AM, Merker VL, Park ER, et al. Quality of life 
among children and adolescents with neurofibromatosis 1: 
a systematic review of the literature. J Neurooncol 2015; 
122(2): 219–228.
 29. Afridi SK, Leschziner GD and Ferner RE. Prevalence and clin-
ical presentation of headache in a National Neurofibromatosis 
1 Service and impact on quality of life. Am J Med Genet A 
2015; 167A(10): 2282–2285.
 30. Cohen JS, Levy HP, Sloan J, et al. Depression among adults 
with neurofibromatosis type 1: prevalence and impact on qual-
ity of life. Clin Genet 2015; 88(5): 425–430.
 31. Crawford HA, Barton B, Wilson MJ, et al. The impact of neu-
rofibromatosis type 1 on the health and wellbeing of Australian 
adults. J Genet Couns 2015; 24(6): 931–944.
 32. Bicudo NP, De Menezes Neto BF, Da Silvade Avó LR, et al. 
Quality of life in adults with neurofibromatosis 1 in Brazil. J 
Genet Couns 2016; 25(5): 1063–1074.
 33. Lai JS, Jensen SE, Patel ZS, et al. Using a qualitative approach 
to conceptualize concerns of patients with neurofibromatosis 
type 1 associated plexiform neurofibromas (pNF) across the 
lifespan. Am J Med Genet A 2017; 173(1): 79–87.
 34. Ferner RE, Thomas M, Mercer G, et al. Evaluation of qual-
ity of life in adults with neurofibromatosis 1 (NF1) using the 
impact of NF1 on quality of life (INF1-QOL) questionnaire. 
Health Qual Life Outcomes 2017; 15(1): 34–39.
 35. Nutakki K, Varni JW, Steinbrenner S, et al. Development of 
the pediatric quality of life inventory neurofibromatosis type 
1 module items for children, adolescents and young adults: 
qualitative methods. J Neurooncol 2017; 132(1): 135–143.
 36. Hunt SM and McKenna SP. The QLDS: a scale for the meas-
urement of quality of life in depression. Health Policy 1992; 
22(3): 307–319.
 37. McKenna SP and Hunt SM. Conceptual and methodological 
advances in quality of life in psychiatric patients: depression 
and the QLDS. Br J Med Econ 1992; 4: 51–61.
 38. Wilburn J, McKenna SP, Perry-Hinsley D, et al. The impact 
of Dupuytren disease on patient activity and quality of life. J 
Hand Surg Am 2013; 38(6): 1209–1214.
 39. Wilburn J, Twiss J, Kemp K, et al. A qualitative study of 
the impact of Crohn’s disease from a patient’s perspective. 
Frontline Gastroenterol 2017; 8(1): 68–73.
 40. Braun V and Clarke V. Using thematic analysis in psychology. 
Qual Res Psychol 2006; 3: 77–101.
 41. Brown BC, McKenna SP, Siddhi K, et al. The hidden cost of 
skin scars: quality of life after skin scarring. J Plast Reconstr 
Aesthet Surg 2008; 61(9): 1049–1058.
 42. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the 
diagnosis and management of individuals with neurofibroma-
tosis 1. J Med Genet 2007; 44(2): 81–88.
 43. Wilburn J, McKenna SP, Twiss J, et al. Assessing quality of 
life in Crohn’s disease: development and validation of the 
Crohn’s Life Impact Questionnaire (CLIQ). Qual Life Res 
2015; 24(9): 2279–2288.
 44. Doward LC, Spoorenberg A, Cook SA, et al. Development of 
the ASQoL: a quality of life instrument specific to ankylosing 
spondylitis. Ann Rheum Dis 2003; 62(1): 20–26.
 45. McKenna SP, Cook SA, Whalley D, et al. Development of 
the PSORIQoL, a psoriasis-specific measure of quality of life 
designed for use in clinical practice and trials. Br J Dermatol 
2003; 149(2): 323–331.
 46. McKenna SP and Wilburn J. Patient value: its nature, 
measurement, and role in real world evidence studies and 
outcomes-based reimbursement. J Med Econ 2018; 21(5): 
474–480.
 47. Cervera-Enguix S, Soutullo CA, Landecho I, et al. Quality of 
life in 833 outpatients with major depression treated with open-
label venlafaxine extended release: an observational 24-week 
study. Int J Psychiatry Clin Pract 2003; 7(3): 193–197.
 48. Cozzani E, Borrini V, Pennella A, et al. The quality of life in 
Italian psoriatic patients treated with biological drugs. G Ital 
Dermatol Venereol 2010; 145(6): 709–712.
 49. Deodhar AA, Dougados M, Baeten DL, et al. Effect of 
secukinumab on patient-reported outcomes in patients with 
Heaney et al. 9
active ankylosing spondylitis: a phase III randomized trial 
(MEASURE 1). Arthritis Rheumatol 2016; 68(12): 2901–2910.
 50. Olczyk J, Kokoszko A, Lewinski A, et al. Quality of life and 
exercise capacity in obesity and growth hormone deficiency. 
Neuro Endocrinol Lett 2010; 31(5): 700–707.
 51. Pitsilka DA, Kafetsios K and Niakas D. Social support and 
quality of life in patients with rheumatoid arthritis in Greece. 
Clin Exp Rheumatol 2015; 33(1): 27–33.
 52. Kisacik P, Unal E, Akman U, et al. Investigating the effects 
of a multidimensional exercise program on symptoms and 
antiinflammatory status in female patients with anky-
losing spondylitis. Complement Ther Clin Pract 2016; 
22: 38–43.
 53. Babovic S, Bite U, Karnes PS, et al. Liposuction: a less inva-
sive surgical method of debulking plexiform neurofibromas. 
Dermatol Surg 2003; 29(7): 785–787.
